AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 9.4% – Still a Buy?

Posted by Brian Himes on Jun 24th, 2026

AbCellera Biologics Inc. (NASDAQ:ABCL – Get Free Report) was up 9.4% during mid-day trading on Wednesday . The company traded as high as $6.10 and last traded at $6.1610. Approximately 3,828,462 shares were traded during trading, a decline of 29% from the average session volume of 5,414,288 shares. The stock had previously closed at $5.63.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on ABCL shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of AbCellera Biologics in a research note on Monday, April 20th. JonesTrading initiated coverage on AbCellera Biologics in a research report on Friday, April 10th. They issued a “buy” rating and a $11.00 target price for the company. Wall Street Zen lowered AbCellera Biologics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Cantor Fitzgerald began coverage on AbCellera Biologics in a research report on Tuesday, May 5th. They set an “overweight” rating and a $7.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.80.

View Our Latest Analysis on AbCellera Biologics

AbCellera Biologics Price Performance

The company has a 50 day moving average of $4.89 and a 200-day moving average of $4.04. The company has a market cap of $1.88 billion, a P/E ratio of -12.85 and a beta of 1.18.

AbCellera Biologics (NASDAQ:ABCL – Get Free Report) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.08. The business had revenue of $8.31 million during the quarter, compared to analysts’ expectations of $5.41 million. AbCellera Biologics had a negative net margin of 181.75% and a negative return on equity of 14.86%. During the same quarter in the previous year, the company earned ($0.15) EPS. Research analysts anticipate that AbCellera Biologics Inc. will post -0.67 EPS for the current year.

Institutional Investors Weigh In On AbCellera Biologics

A number of large investors have recently added to or reduced their stakes in ABCL. AssuredPartners Investment Advisors LLC bought a new position in AbCellera Biologics during the 4th quarter valued at approximately $34,000. Engineers Gate Manager LP bought a new stake in shares of AbCellera Biologics in the 4th quarter worth approximately $38,000. Allworth Financial LP increased its stake in shares of AbCellera Biologics by 857.0% during the fourth quarter. Allworth Financial LP now owns 11,274 shares of the company’s stock valued at $39,000 after buying an additional 10,096 shares during the period. Janney Montgomery Scott LLC purchased a new position in shares of AbCellera Biologics during the first quarter valued at approximately $46,000. Finally, Magnetar Financial LLC bought a new position in shares of AbCellera Biologics during the fourth quarter valued at approximately $49,000. Institutional investors own 61.42% of the company’s stock.

About AbCellera Biologics

(Get Free Report)

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.